Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE3075.0062.85 (+2.09 %)

PREV CLOSE ( ) 3012.15

OPEN PRICE ( ) 3057.70

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8027

TODAY'S LOW / HIGH ( )2981.00 3087.00

52 WK LOW / HIGH ( )2335 3314.8

NSE3074.9057.7 (+1.91 %)

PREV CLOSE( ) 3017.20

OPEN PRICE ( ) 3040.80

BID PRICE (QTY) 3074.90 (805)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 182466

TODAY'S LOW / HIGH( ) 2982.00 3089.20

52 WK LOW / HIGH ( )2329.9 3314.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta Tower, 54 - A,M V Road, Chakala,Andheri (East),
Mumbai,
Maharashtra-400093

Phone 022-60609000 / 66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

10Jun Ajanta Pharma’s promoter sells stake w
Ajanta Pharma’s promoter entity -- Ravi Agrawal Trust has sold 34.50 lak..

10Jun Ajanta Pharma trades higher on the bou
Ajanta Pharma is currently trading at Rs. 3075.00, up by 62.85 points or..

09Jun Ajanta Pharma informs about SAST updates
Ajanta Pharma has informed that it enclosed Disclosure under Regulation..

09Jun Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that it enclosed disclosure under Regulation..

02Jun Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that it enclosed Disclosure under Regulation..

Financials

Rs. in Millions

	QTR Mar 26	ANNUAL 26
Net Profit	1972.8	9468.2
Gross Profit	2576.1	12310.3
Operating Profit	3010.3	14023.9
Net Sales	12105.3	48459.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 26544.35 (1.52%)	M.Cap ( in Cr)56404.89
Kwality Pharma (BSE) 2500.00 (7.01%)	M.Cap ( in Cr)2594.05
Unichem Lab (BSE) 439.40 (16.23%)	M.Cap ( in Cr)3093.63
Caplin Point Lab (BSE) 2311.25 (2.38%)	M.Cap ( in Cr)17568.20
Concord Biotech (BSE) 1322.25 (3.99%)	M.Cap ( in Cr)13832.88

Shareholding Pattern

	PROMOTERS	66.25%
	MUTUAL FUNDS/UTI	15.22%
	NON-INSTITUTION	7.12%
	FI/BANKS/INSURANCE	2.7%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	4.92
Aditya Birla SL Pha...	3.96
NJ ELSS Tax Saver S...	3.47
PGIM India Healthca...	3.28
NJ Flexi Cap Fund-Reg(G)	3.10
Nippon India Pharma...	2.88
Kotak Healthcare Fu...	2.24

Risk Disclosures on Derivatives

Smart Quotes

AJANTA PHARMA LTD.